Published in Drug Alcohol Depend on June 05, 2003
MOms in REcovery (MORE) Study: Defining Optimal Care (MORE) | NCT04251208
Substance abuse treatment entry, retention, and outcome in women: a review of the literature. Drug Alcohol Depend (2006) 5.64
The Effects of Peer Group Network Properties on Drug Use Among Homeless Youth. Am Behav Sci (2005) 1.70
Theory-based processes that promote the remission of substance use disorders. Clin Psychol Rev (2006) 1.69
Social contextual factors associated with entry into opiate agonist treatment among injection drug users. Am J Drug Alcohol Abuse (2005) 1.10
Concurrent heroin use among methadone maintenance clients in China. Addict Behav (2011) 0.98
Ethnic differences in alcohol and drug use and related sexual risks for HIV among vulnerable women in Cape Town, South Africa: implications for interventions. BMC Public Health (2013) 0.94
Initial feasibility of a woman-focused intervention for pregnant african-american women. Int J Pediatr (2011) 0.87
Characteristics and 9-month outcomes of discharged methadone maintenance clients. J Subst Abuse Treat (2010) 0.78
Romance, recovery & community re-entry for criminal justice involved women: Conceptualizing and measuring intimate relationship factors and power. J Gend Stud (2015) 0.76
Should pregnant women with substance use disorders be managed differently? Neuropsychiatry (London) (2012) 0.76
A randomized clinical trial of behavioral couples therapy versus individually-based treatment for drug-abusing women. J Consult Clin Psychol (2017) 0.75
Intrauterine abstinence syndrome (IAS) during buprenorphine inductions and methadone tapers: can we assure the safety of the fetus? J Matern Fetal Neonatal Med (2012) 1.43
Use of buprenorphine in pregnancy: patient management and effects on the neonate. Drug Alcohol Depend (2003) 1.36
Neonatal abstinence syndrome in methadone-exposed infants is altered by level of prenatal tobacco exposure. Drug Alcohol Depend (2004) 1.26
Mood disorders affect drug treatment success of drug-dependent pregnant women. J Subst Abuse Treat (2006) 1.22
A Comparison of Buprenorphine + Naloxone to Buprenorphine and Methadone in the Treatment of Opioid Dependence during Pregnancy: Maternal and Neonatal Outcomes. Subst Abuse (2013) 1.16
Response to Wouldes and Woodward: maternal methadone dose during pregnancy and infant clinical outcome. Neurotoxicol Teratol (2013) 1.15
Buprenorphine + naloxone in the treatment of opioid dependence during pregnancy-initial patient care and outcome data. Am J Addict (2013) 1.10
The impact of managed care on drug-dependent pregnant and postpartum women and their children. Subst Use Misuse (2007) 1.07
Drug use and HIV risk outcomes in opioid-injecting men in the Republic of Georgia: behavioral treatment + naltrexone compared to usual care. Drug Alcohol Depend (2011) 1.02
Comparing homeless and domiciled pregnant substance dependent women on psychosocial characteristics and treatment outcomes. Drug Alcohol Depend (2003) 0.98
Cigarette smoking knowledge, attitudes, and practices of patients and staff at a perinatal substance abuse treatment center. J Subst Abuse Treat (2010) 0.98
Double jeopardy--drug and sex risks among Russian women who inject drugs: initial feasibility and efficacy results of a small randomized controlled trial. Subst Abuse Treat Prev Policy (2012) 0.97
Lessons learned from a randomized trial of fixed and escalating contingency management schedules in opioid-dependent pregnant women. Am J Drug Alcohol Abuse (2012) 0.97
Predicting treatment for neonatal abstinence syndrome in infants born to women maintained on opioid agonist medication. Addiction (2012) 0.96
Co-occurring psychiatric symptoms are associated with increased psychological, social, and medical impairment in opioid dependent pregnant women. Am J Addict (2010) 0.95
Fetal neurobehavioral effects of exposure to methadone or buprenorphine. Neurotoxicol Teratol (2010) 0.94
Twice stigmatized: provider's perspectives on drug-using women in the Republic of Georgia. J Psychoactive Drugs (2013) 0.94
The impact of mood disorders on the delivery and neonatal outcomes of methadone-maintained pregnant patients. Am J Drug Alcohol Abuse (2009) 0.93
Psychopharmacologic management of opioid-dependent women during pregnancy. Am J Addict (2009) 0.92
Determination of methadone, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine, 2-ethyl-5-methyl-3,3-diphenylpyraline and methadol in meconium by liquid chromatography atmospheric pressure chemical ionization tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2005) 0.92
Partner violence impacts the psychosocial and psychiatric status of pregnant, drug-dependent women. Addict Behav (2004) 0.91
Relationship between cigarette use and mood/anxiety disorders among pregnant methadone-maintained patients. Am J Addict (2009) 0.91
Neonatal neurobehavior effects following buprenorphine versus methadone exposure. Addiction (2012) 0.88
Behavioral treatment + naltrexone reduces drug use and legal problems in the Republic of Georgia. Am J Drug Alcohol Abuse (2012) 0.87
Fetal assessment before and after dosing with buprenorphine or methadone. Addiction (2012) 0.87
Post-cesarean pain management of patients maintained on methadone or buprenorphine. Am J Addict (2006) 0.85
A comparison of cigarette smoking profiles in opioid-dependent pregnant patients receiving methadone or buprenorphine. Nicotine Tob Res (2013) 0.85
Maternal treatment with opioid analgesics and risk for birth defects: additional considerations. Am J Obstet Gynecol (2011) 0.85
Buprenorphine and norbuprenorphine in hair of pregnant women and their infants after controlled buprenorphine administration. Clin Chem (2007) 0.85
Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates. Addiction (2012) 0.82
Abstinence-contingent recovery housing and reinforcement-based treatment following opioid detoxification. Addiction (2012) 0.81
Effect of hepatitis C virus status on liver enzymes in opioid-dependent pregnant women maintained on opioid-agonist medication. Addiction (2012) 0.81
Methadone and metabolites in hair of methadone-assisted pregnant women and their infants. Ther Drug Monit (2012) 0.80
Usefulness of salivary trans-3'-hydroxycotinine concentration and trans-3'-hydroxycotinine/cotinine ratio as biomarkers of cigarette smoke in pregnant women. J Anal Toxicol (2005) 0.80
The efficacy of escalating and fixed contingency management reinforcement on illicit drug use in opioid-dependent pregnant women. Addict Disord Their Treat (2012) 0.79
The relationship between antidepressant use and smoking cessation in pregnant women in treatment for substance abuse. Am J Drug Alcohol Abuse (2010) 0.78
Excretion of methadone in sweat of pregnant women throughout gestation after controlled methadone administration. Ther Drug Monit (2010) 0.78
Female partners of opioid-injecting men in the Republic of Georgia: an initial characterization. Subst Abuse Treat Prev Policy (2012) 0.78
Opioid dependence during pregnancy: relationships of anxiety and depression symptoms to treatment outcomes. Addiction (2012) 0.78
Screening for Mood Disorder in Pregnant Substance-dependent Patients. Addict Disord Their Treat (2009) 0.77
Methadone and the causes of maternal and perinatal complications: a response to Pinto et al. "Substance abuse during pregnancy: effect on pregnancy outcomes" [Eur. J. Obstet. Gynecol. Reprod. Biol. 150 (2010) 137-141]. Eur J Obstet Gynecol Reprod Biol (2011) 0.77
Infections and obstetric outcomes in opioid-dependent pregnant women maintained on methadone or buprenorphine. Addiction (2012) 0.77
Methadone and perinatal outcomes: another perspective. Am J Obstet Gynecol (2011) 0.76
Comments on: Efficacy versus effectiveness of buprenorphine and methadone maintenance in pregnancy. J Addict Dis (2012) 0.75
Cigarette Smoking and Neonatal Outcomes in Depressed and Non-Depressed Opioid-Dependent Agonist-Maintained Pregnant Patients. Addict Disord Their Treat (2011) 0.75
Treating Women Who Are Pregnant and Parenting for Opioid Use Disorder and the Concurrent Care of Their Infants and Children: Literature Review to Support National Guidance. J Addict Med (2017) 0.75